Compugen (CGEN) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research downgraded shares of Compugen (NASDAQ:CGEN) from a buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports.

According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “

Other research analysts have also recently issued reports about the company. Oppenheimer set a $9.00 price objective on Compugen and gave the company a buy rating in a report on Tuesday, February 26th. ValuEngine upgraded Compugen from a sell rating to a hold rating in a report on Wednesday, January 2nd.

CGEN opened at $3.49 on Tuesday. Compugen has a one year low of $2.00 and a one year high of $4.31. The company has a market capitalization of $179.01 million, a P/E ratio of -8.51 and a beta of 2.43.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Tuesday, February 26th. The biotechnology company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.05. Equities analysts anticipate that Compugen will post -0.57 EPS for the current fiscal year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. RBF Capital LLC acquired a new position in Compugen in the fourth quarter valued at approximately $30,000. Cornerstone Investment Partners LLC acquired a new position in Compugen in the fourth quarter valued at approximately $38,000. Millennium Management LLC acquired a new position in Compugen during the fourth quarter worth $60,000. Jane Street Group LLC acquired a new position in Compugen during the third quarter worth $128,000. Finally, Virtu Financial LLC acquired a new position in Compugen during the first quarter worth $153,000. Hedge funds and other institutional investors own 23.57% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

See Also: Investing strategies using the yield curve

Get a free copy of the Zacks research report on Compugen (CGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.